Full Press Release Details
Kamada Files Annual Report for the Year
Ended December 31, 2019
Israel, February 26, 2020 - Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today
announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019, with the U.S. Securities
and Exchange Commission (the "SEC").
The annual report, including the Company's
audited consolidated financial statements, can be accessed via the SEC's website at https://www.sec.gov/edgar.shtml, as well
as under the SEC Filings section on Kamada's investor relations website at https://www.kamada.com/.
The Company will deliver a hard copy of
its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests
should be directed to Kamada's Investor Relations Department at IR@kamada.com.
Kamada Ltd. ("the Company")
is a plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio and a
late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification
of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived
immune globulins. The Company's flagship product is GLASSIA ("GLASSIA"), the first liquid, ready-to-use,
intravenous plasma-derived AAT product approved by the U.S. FDA. The Company markets GLASSIA in the U.S. through a strategic partnership
with Takeda Pharmaceuticals Company Limited and in other counties through local distributors. The Company's second leading
product is KamRab, a rabies immune globulin (Human) for post-exposure prophylaxis against rabies infection. KamRab is FDA approved
and is being marketed in the U.S. under the brand name KEDRAB through a strategic partnership with Kedrion S.p.A. In addition
to Glassia and KEDRAB, the Company has a product line of four other plasma-derived pharmaceutical products administered by injection
or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other
countries in Latin America and Asia. The Company has late-stage products in development, including an inhaled formulation of AAT
for the treatment of AAT deficiency. In addition, the Company's intravenous AAT is in development for other indications,
such as GvHD and prevention of lung transplant rejection. The Company leverages its expertise and presence in the plasma-derived
protein therapeutics market by distributing more than 20 complementary products in Israel that are manufactured by third parties.
Chief Financial Officer
LifeSci Advisors, LLC